Merck is looking for stability at the top of its human health business after turnover in the past year.
Frank Clyburn, who most recently served as president of the human health business, last month announced he would depart to take the CEO role at IFF, a New York-based maker of ingredients for food, fragrances and health products.
Clyburn hadn’t yet served a year in the position. He took over in March 2021 from Michael Nally, who himself left for a CEO job at another company.
The New Jersey-based drugmaker has been rebuilding its leadership team after the departure of long-time CEO Kenneth Frazier and research chief Roger Perlmutter in 2021. While the company is conducting an external search for its new Human Health International chief, its other choices show a willingness to promote from within.
Garay has been with the company since 2006 and previously led pharmaceutical global marketing, commercial analytics and digital marketing. Oosthuizen, who formerly helmed Merck’s business in Japan as well as oncology operations in the Asia Pacific and Latin America, has worked at the company since 2014 after a two-decade career at Eli Lilly.
Khanna, meanwhile, has been at Merck since 1988, working his way up from field sales to top roles in the oncology business. The three executives will assume their human health posts as of Feb. 28. They will sit on the executive team and report directly to CEO Robert Davis, Merck said.
By Kristin Jensen
Source: biopharmadive.com
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).
